Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
36 hedge funds and large institutions have $171M invested in Vincerx Pharma, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
115% more capital invested
Capital invested by funds: $79.5M → $171M (+$91.5M)
100% more funds holding
Funds holding: 18 → 36 (+18)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRC
Sage Rhino Capital
Menlo Park,
California
|
+$32.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.8M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$10.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$10.1M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$9.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$6.27M |
| 3 |
ACM
Altium Capital Management
New York
|
-$3.14M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.02M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.02M |
VINC Hedge Fund Activity: Q1 2021 in Review
36 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q1 2021, worth a combined $171M — up 115% from $79.5M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new VINC positions and 4 closed out — a net gain of 18 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Sage Rhino Capital, opening a new position worth an estimated $32.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10M sold.
- 36 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q1 2021, up from 18 in Q4 2020.
- Funds reported $171M of Vincerx Pharma, Inc. Common Stock stock for Q1 2021, up 115% quarter-over-quarter.
- 22 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q1 2021 and 4 closed out, a net change of +18 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q1 2021 was Sage Rhino Capital, an estimated $32.6M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q1 2021 was EcoR1 Capital, an estimated $10M sold.
Based on aggregated 13F filings for Q1 2021.